As of June 2025, the branded version of liraglutide, Saxenda, generated $165 million in annual sales alone, and the market for GLP-1s could be set to hit over $126 billion in sales by 2029
GLP1 Drugs (Wegovy, Zepbound): Pros: Highly effective, non-invasive, strong appetite suppression, rapid results
A L-Carnitine supplement is commonly used during cutting phases, endurance training, or periods of increased physical demand
This represents the cash-pay price for the FDA-approved, brand-name product
(Raufman, more interested in research, relinquished his rights.) Eng took it to the VA first, which showed little interest